ew Paper
trategies
e System
mmune
mmune syster system, Micr

Due to antigenic variation, pathogenic micro-organisms can escape the immune system. Microorganisms can occur in different types, such as the 97 serotypes of *Streptococcus pneumoniae*. Influenza viruses change their antigenic make-up, in particular the hemagglutinin molecule by antigenic drift and antigenic shift. Trypanosomes and malaria parasites use DNA programmed expression of highly variable surface antigens. Micro-organisms can also produce proteins that degrade (IgA protease) or inactivate antibody molecules (protein A and protein G). Some bacteria and viruses produce proteins that inhibit complement activation. Virus can become invisible for recognition by T-lymphocytes by interference with antigen presentation. Antiviral immunity can be suppressed by viral homologues of cytokines and cytokine receptors and other proteins. Despite the extensive immune evasion strategies used by viruses, bacteria and other micro-organisms, the immune system in most cases is ultimately able to control an infection.

12 13

14

15 16 Keywords: evasion mechanisms, IgA proteases, capsular polysaccharides, antigenic drift, antigenic shift, complement inhibitors, antigen presentation, cytokine homologues

## 17 1. INTRODUCTION

18

19 Micro-organisms and parasites use a number of different ways to escape the immune system. The 20 Christian religious history has the legend of Saint Julia, who tried to escape from her future husband. The story of this legend is that in the 14<sup>th</sup> century, Julia, the daughter of a heathen King in Portugal, 21 was promised by her father to be the bride of the King of Sicily. Julia refused because she wanted to 22 23 remain a virgin and in order to prevent she had to marry, she prayed to God for help. Soon thereafter 24 she grew a beard and her husband-to-be then refused her. Unfortunately Julia's father became so mad that this prearranged marriage was cancelled that he had her crucified. Saint Julia has been 25 popular through the ages and her crucifixion is depicted in many works of art, including statues, 26 drawings and paintings [1]. The scene of her crucifixion is also depicted by Jheronimus Bosch in the 27 Martyrdom of Saint Julia (Figure 1). For the occasion of the 600<sup>th</sup> anniversary of Jheronimus Bosch in 28 29 2016, the painting was loaned by the Gallerie dell'Accademia, Venice, Italy to the Noord-Brabants Museum in 's Hertogenbosch, The Netherlands, the home town of Jheronimus Bosch. As a part of the 30 31 deal the painting was fully restored and only then the beard of Saint Julia became clearly visible. 32 Growing a beard as a strategy to escape marriage.

34 35

36 Figure 1.

37 Detail of the painting The Martyrdom of Saint Julia by Jheronimus Bosch (around 1497). The painting

38 is alternatively named Saint Wilgefortis Triptych, because Saint Julia had such as strong (fortis) will

39 (wilge). Gallerie dell'Accademia, Venice, Italy.

40 (http://boschproject.org/#/artworks/Saint\_Wilgefortis\_Triptych).

41

42 **COMMENTS**: I don't know the reasons for the inclusion of the above lines in red but, for 43 me, I am of the opinion (without any motive of being anti-Christ) that the lines may not be 44 necessary unless the author has strong and academically justifiable reasons for their 45 inclusion.

46

47 Various microorganisms and parasites have evolved different strategies to escape the immune 48 system of the host. This strategy is called evasion. Evasive mechanisms contribute strongly to the 49 virulence and pathogenicity of these organisms. Different categories of evasive mechanisms can be 50 distinguished, each with different targets on the immune system, which will be discussed in this 51 review.

- 52
- 53
- 54
- 55
- 56
- 57
- 58



#### 59 2. IMMUNE EVASION MECHANISMS


# 60 **2.1 Due to antigenic variation pathogenic micro-organisms can escape the immune**

## 61 system

62 One of the ways in which a microorganism can escape elimination by the immune system is by 63 altering its antigenic make up [2]. Such a makeover can occur in three different ways.

First, a micro-organism can occur in different types. For example, the bacterium *Streptococcus pneumoniae* has ninety seven serotypes that differ in the structure of the capsular polysaccharide [Figure 2] [3]. Infection with a given serotype leads to type-specific immunity, which, however, does not protect against infection with any of the other pneumococcal serotypes [4]. For the acquired immune system, every pneumococcal serotype is therefore a separate micro-organism. This means that *Streptococcus pneumoniae* can cause a primary infection several times in the same individual.

70



71

Figure 2.

73 Streptococcus pneumoniae, a Gram-positive facultative anaerobic bacterium is encapsulated by a

thick layer of polysaccharides (arrow in left panel). The capsule is made up by one of 93 different

types of polysaccharides; the structural composition of four common occurring serotypes is shown in
the right-hand panel.


77

# 78 COMMENT: What is the source and year of the above figure 2 ?

79

80 A second way of antigenic variation is more dynamic and is found among others in the influenza virus, 81 the cause of influenza. There are three different types of influenza virus, A, B and C, of which 82 influenza A causes the most serious disease symptoms [5]. Most infections that occur worldwide during the influenza season (autumn and winter) are caused by a single type of the influenza A virus. 83 84 Over time, protective immunity arises in the population, which mainly consists of antibodies and 85 cytotoxic T-lymphocytes directed against the viral hemagglutinin protein [6]. The hemagglutinin is 86 involved in attachment to target cells and antibodies against hemagglutinin can (thereby) prevent the spread of the virus in the body [7, 8]. Due to changes in the hemagglutinin protein (see below), a virus 87 88 type is created against which the accumulated immunity in the population does not work or does not 89 function properly [9]. Such a changed virus can therefore cause a new infection. The influenza virus 90 can alter the antigenic makeup of the hemagglutinin in two ways: antigenic drift and antigenic shift

91 (Figure 3) [10]. Mutations in the gene coding for the hemagglutinin (and for the second important virus 92 surface protein neuraminidase) produce a new variant of the influenza virus (antigenic drift) every two 93 or three years [11]. This variant is less well recognized by the antibodies and cytotoxic T lymphocytes 94 present. This allows the influenza virus to cause a - generally mild - flu epidemic [12]. Such an 95 epidemic is mild because although some epitopes of the hemagglutinin and / or neuraminidase have 96 changed, not all of them have. So there is still a certain amount of residual immunity in the population. Antigenic shift is a much rarer event, but with far greater consequences [13]. An antigenic shift can 97 98 occur when a (human) influenza A virus ends up in a secondary host (e.g. a bird). The influenza RNA 99 genome is segmented into eight genes, one of which is coding for hemagglutinin and one for 100 neuraminidase [14]. In a secondary host, in a cell that is infected with two different influenza viruses, 101 exchange of a complete RNA segment can take place [15]. Thus, in a host cell infected with both the 102 human and avian influenza virus, exchanges between both viruses can occur. From this, a (human) 103 virus variant can emerge with an avian hemagglutinin (Figure 3). At least 18 subtypes of the 104 hemagglutinin occur (H1 to H18), of neuraminidase 11 (N1 to N11) [16]. The most common influenza 105 A types in humans are H1N1, H2N2 and H3N2 [17]. H5, H6, H7 and H8 are especially common in 106 birds [18]. Due to antigenic shift, the H5N1 variant originated in which the avian H5 ended up in a 107 human influenza A virus [19, 20]. The differences between the human and avian influenza 108 hemagglutinin are so great that antibodies and cytotoxic T lymphocytes formed during previous 109 infections do not give any cross protection. Influenza strains in which such an antigenic shift has occurred occur once every 15 to 20 years [10]. The so-called Hong Kong influenza pandemic in 1968, 110 111 with world-wide one million deaths, was caused by a virus variant due to antigenic shift [19, 21]. 112



113

114 Figure 3.

115 Antigenic shift and antigenic drift of influenza A virus. The major surface antigens of the influenza A

116 virus are hemagglutinin and neuraminidase. By point mutations in the RNA encoding hemagglutinin,

117 the antigenic make-up of the molecule can change somewhat. This is called antigenic drift. This

allows original antibodies to bind less well or not at all and the mutated virus has a better chance of

119 survival. In an antigenic shift, two different influenza A virus particles exchange a complete RNA

120 segment, allowing a completely different hemagglutinin molecule to be expressed. Accumulated

- 121 immunological memory from previous influenza contacts is then no longer effective because
- 122 antibodies (and memory T lymphocytes) no longer recognize the altered hemagglutinin molecule.
- 123 Such an altered influenza virus is therefore more easily able to cause an epidemic.
- 124

# 125 COMMENTS: What is the source and year of Figure 3 ?

126

The most recent influenza pandemic started in Mexico in 2009 and was initially called swine flu. Later, under pressure from Mexico, this name was changed to new influenza A (N1H1) (Figure 4). What was special was that this variant particularly affected young children, while normally older people are particularly susceptible to influenza [22, 23]. In retrospect, many people aged about 50 years and older were already found to have (cross-reactive and protective) antibodies against this virus, due to exposure to a similar influenza in their youth [24]. The N1H1 spread rapidly around the world, and initially there was fear that millions of people would be killed.

134 A vaccine against H1N1 has been accelerated and offered to major risk groups i.e. children between 135 6 months and 4 years, household members of younger children, and adults with chronic disease [25]. 136 In retrospect, the H1N1 pandemic was mild, probably mainly because the elderly - in which the 137 mortality is concentrated during the annual flu season - were barely susceptible to the new influenza 138 A (N1H1) [24]. An estimated 300,000 people worldwide have died directly or indirectly from the virus 139 [26]. A total of 65,600 deaths was confirmed in Africa, 29,700 in the Americas, 31,000 in Europe, and 78,600 in Asia [26]. At the moment the H1N1 vaccine became available, the peak of the pandemic 140 141 might already have passed.

142

NATIONAL



Hot arrivals from Mexico face swine flu scrutiny CHIBA (kyodo) Japan went on high alert for swine flu Saturday in light of the deadly outbreaks in Mexico, tightening health checks and inspections on passengers and live pigs arriving from the country.



W.H.O. Estimate of Swine Flu Deaths in 2009 Rises Sharply



Quarantine brings love in the time of swine flu at Hong Kong hotel

First Asian case was traced to Hong Kong hotel
 Guests locked in for week tell of parties and romance



- 143
- 144 Figure 4.
- 145 Worldwide outbreak of new N1H1 influenza virus in 2009, as reported in the press and communicated
- 146 to travelers.
- 147

The third way in which antigenic variation can occur is due to programmed changes in the DNA of the micro-organism or the parasite [27]. In its most extreme form, this mechanism is used by 150 trypanosomes. Trypanosomes are protozoans that are transmitted by insects and cause sleeping sickness [28, 29]. The trypanosome is surrounded by a single protein, the variant-specific glycoprotein 151 152 (VSG) [30]. After infection, this VSG generates a powerful antibody response that neutralizes the 153 parasite. However, trypanosomes have a thousand different VSG genes of which only one is 154 expressed each time. The single trypanosome that has been altered from VSG expression thus 155 escapes the immune system and leads to renewed outgrowth and flare-up of the disease [30]. This will result in a chronic cycle of trypanosome degradation with immune complex formation and 156 157 inflammation, followed by renewed disease activity. Ultimately, this leads to severe neurological 158 damage and coma.

159 The malaria parasite also uses this mechanism of antigenic variation to protect itself against the 160 immune system [31]. In the erythrocyte stage of malaria there is expression of parasite proteins on the 161 membrane of the red blood cell, especially of the PfEMP1 protein [32, 33]. The PfEMP1 protein 162 suppresses the production of IFN- $\gamma$  and thus a cellular immune response [34]. Via PfEMP1 an infected erythrocyte adheres to vascular wall tissue and can thus prevent phagocytosis by spleen 163 164 macrophages. PfEMP1 does elicit an antibody response and these antibodies can bind to infected 165 erythrocytes. Antibody-loaded erythrocytes are captured in the spleen and phagocytosed. The malaria parasite has sixty variants of PfEMP1, of which only one is expressed each time [35]. Switching to 166 another variant of PfEMP1 means that the already produced antibodies can no longer bind and that 167 168 infected erythrocytes are no longer trapped.

#### 169 **2.2 Micro-organisms produce proteins that can degrade or inactivate antibody**

#### 170 molecules

171 Micro-organisms can protect against antibody-mediated complement lysis or phagocytosis by 172 enzymatic degradation of the antibodies. A number of bacteria, including Neisseria species, 173 Haemophilus influenzae and Streptococcus pneumoniae form proteolytic enzymes that can split 174 secretory IgA (SIgA) antibodies into two monomeric Fab fragments and an Fc fragment [36, 37]. This IgA protease is capable of cleaving both free SIgA and bound SIgA antibodies. The Fab fragments 175 176 remain on the surface of the microorganism but are unable to activate effector mechanisms 177 (complement, phagocytosis) [38]. Infections with the above bacteria occur on mucous membranes 178 and IgA is the most important isotype of the antibodies present [39]. The bacterial IgA proteases are 179 especially capable of splitting SIgA1 while SIgA2 is relatively resistant to IgA proteases [36, 37]. But 180 because the IgA1 Fab fragments remain bound on the surface of the microorganism, binding of IgA2 181 antibodies can be inhibited thereby [40, 41].

- 182 IgG antibodies can also be broken down by bacterial enzymes. *Pseudomonas aeruginosa* and other
  183 bacteria produce cysteine proteases that can cleave IgG molecules at the hinge region.
- Besides proteolytic cleavage of the molecule, IgG can also be functionally inactivated by certain bacterial proteins [42-44]. *Staphylococcus aureus* expresses a protein on its surface called protein A, which can bind to the Fc portion of IgG. Binding of protein A to IgG blocks Fc receptor-mediated phagocytosis [45, 46]. Moreover, it inhibits the binding of C1q to IgG and thus complement activation

- [47]. In other bacteria, proteins with similar functions are found: Group-G streptococcci produce protein
   G and *Peptostreptococcus* produces protein-L. These proteins can also bind to IgG [48-50].
- 190 **2.3 Some bacteria and viruses produce proteins that inhibit complement activation**

191 Many bacteria produce N-formyl peptides such as fMLP [51]. These peptides are very potent 192 chemoattractants for phagocytes [52]. fMLP is bound to phagocytes via specific receptors: formyl 193 peptide receptor (FPR) and the related FPR-like-1 receptor (FPRL1) [53]. The fMLP is not only a 194 chemoattractant but also stimulates phagocytosis [54, 55]. Staphylococcus aureus has developed a 195 strategy to prevent the attraction of phagocytes to the site of the infection by producing the protein 196 CHIPS (chemotaxis inhibiting protein of S. aureus) [56]. CHIPS binds to FPRL1 and thus blocks the 197 functioning of this receptor [57]. CHIPS also binds to the C5a receptor on phagocytes and thereby 198 blocks the function of another chemotactic peptide, the complement fragment C5a [58]. Another staphylococcal protein that interferes with the complement system is SCIN (staphylococcal 199 200 complement inhibitor) [59]. SCIN blocks the C3 converter activity of C4b2a and C3bBb [60-62]. In 201 total, S. aureus possesses about ten different proteins that can all inhibit complement activation. 202 Together, this will disrupt all functions mediated by the complement system (chemotaxis and lysis and 203 opsonization) [62-64]. These and other proteins that are used to escape the immune system of the 204 host lie encoded on the bacterial genome together in a so-called immune vascular cluster (IEC), of 205 which S. aureus possesses two [65, 66].

- Not only *S. aureus* and other bacteria use proteins to prevent activation of the complement system (Figure 5) but also certain viruses. Vaccinia virus encodes a strong complement inhibitor, vaccinia complement control protein (VCP). VCP strengthens the split of C3b and C4b by factor I and thus inhibits both the classic and alternative complement activation path [67-70].
- 210

## 211 **2.4 Interference with antigen presentation makes viruses invisible for recognition by**

## 212 T-lymphocytes

Viruses have developed different ways to escape the immune system. It is of course important that virus replication occurs only in host cells, where the virus is not immediately accessible to the immune system. During viral replication, components of viral proteins are presented to the immune system by MHC class I and class II proteins. In that way the virus would betray its presence in an infected cell. However, if the virus does not replicate, but remains latent, it is invisible.

218 Herpes simplex virus type I infects epithelial cells and sensory neurons [71]. After a cellular immune 219 response the infection is under control, but the virus can still remain latent in the nerve cells [72]. 220 Reactivation of the virus can, if the antiviral immunity is reduced or temporarily disturbed, lead to a re-221 infection of the skin [73]. Another herpes virus, the previously discussed Epstein-Barr virus, can 222 remain latent in B lymphocytes [74]. For this it must express a certain viral protein, EBNA-1, since this 223 is necessary to maintain the viral genome. EBNA-1 cannot be presented in the context of MHC class 224 I, because it cannot be broken down by the proteasome. This keeps the virus invisible to the immune 225 system [75-77].

226 Other viruses also have proteins that interfere with antigen presentation and thus try to prevent a 227 cellular immune response from getting under way. For example, the cytomegalovirus (CMV) has at 228 least twelve different proteins that block the presentation of CMV peptides in the MHC at different 229 sites [78]. These CMV proteins are encoded on the unique long (UL), or unique short (unique short, 230 US) part of the CMV genome [79]. US3 and US10 proteins prevent MHC class I molecules from 231 leaving the endoplasmic reticulum [80, 81]. If nonetheless MHC class I molecules are formed, US2 232 and US11 proteins bind to this, after which the MHC molecules are degraded by proteasomes [82, 233 83]. Disabling MHC class I expression prevents recognition by cytotoxic T lymphocytes, but makes the cell susceptible to killing by NK cells [84]. The CMV protein UL16, however, blocks the activating 234 235 NK cell receptor NKD2D and UL18 stimulates the inhibitory NK cell receptors [85, 86]. CMV therefore 236 has an extensive package of viral proteins at its disposal to combat killing by CD8<sup>+</sup> T lymphocytes or 237 by NK cells.

238

#### 239 **2.5** Viral homologues of cytokines and cytokine receptors and other proteins


## 240 suppress antiviral immunity

241 If a virus, despite its attempts to prevent recognition by the immune system, would still evoke an 242 immune response, it can try to suppress that response. One of the strategies employed is that the 243 viral genome encodes homologues of suppressive cytokines and/or soluble cytokine receptors. [87-90]. EBV encodes a viral homolog of IL-10, which is very similar to human IL-10 but has only its 244 245 immunosuppressive properties [91, 92]. EBV also encodes an IL-12p40 related protein [93]. Pox viruses use soluble cytokine receptor homologous proteins and cytokine binding proteins to neutralize 246 247 proinflammatory cytokines [94]. These viruses also code for a soluble chemokine antagonist that binds with high affinity to CC-chemokines .Fungi also use inhibition of cytokines to escape the 248 249 immune response of the host. Virulent cryptococcal strains secrete proteins with anti-TNF-α and anti-250 IL-12 activity, while stimulating the IL-10 production of the host [95].

In addition to blockade of the cytokine function, viruses can also neutralize the action of antibodies by synthesis of viral Fc receptors (herpes simplex and cytomegalovirus) [96, 97]. Finally, viruses can also resist apoptosis in order to escape cytotoxic T lymphocytes and NK cells. The most successful is the adenovirus, which possesses a protein that is very similar to the anti-apoptotic Bcl-2. EBV also has two proteins that resemble Bcl-2 [98]. Inhibition of caspase activity and reduction of the expression of apoptosis receptors such as FasL are other ways in which viruses prevent apoptosis [99-101].

257 Despite the extensive immune evasion strategies used by viruses, bacteria and other micro-258 organisms, the immune system in most cases is ultimately able to control an infection. However, when 259 components of the immune system do not function adequately, such as with congenital or acquired

260 immune deficiencies, even seemingly innocent microorganisms can lead to serious infections.



262 Figure 5.

263 Complement evasion by bacterial proteins. Figures shows examples of bacterial proteins which can

264 interfere with specific pathways of the complement system. Further explanation is given in the text.

265

261

## 266 COMMENTS: What is the source and year of Figure 5 ?

## 267 3. EPILOGUE

Saint Julia, by changing her antigenic make up, tried to evade from her husband to be. This relief was only temporary, because another man, notably her own father, had her crucified. The analogy with micro-organisms that try to escape the immune system partly holds true. Escape from complement mediated killing does not prevent phagocytosis and subsequent intracellular killing.

272

273

274

## 275 **REFERENCES**

276

Friesen IE. The female crucifix: Images of St. Wilgefortis. Waterloo, Ontario, Canada:
 Wilfried Laurier University Press; 2001.

- Hornef MW, Wick MJ, Rhen M, Normark S. Bacterial strategies for overcoming host
   innate and adaptive immune responses. Nat Immunol. 2002;3(11):1033-40. doi:
   10.1038/ni1102-1033
- Geno KA, Gilbert GL, Song JY, Skovsted IC, Klugman KP, Jones C, et al.
   Pneumococcal capsules and their types: past, present, and future. Clin Microbiol
   Rev. 2015;28(3):871-99. doi: 10.1128/cmr.00024-15
- Brown J, Hammerschmidt, S., Orihuela, C. *Streptococcus pneumoniae*: molecular
   mechanisms of host-pathogen interactions. San Diego, CA: Elsevier; 2015.
- 287 5. Ghebrehewet S, MacPherson P, Ho A. Influenza. Bmj. 2016;355:i6258. doi:
  288 10.1136/bmj.i6258
- 289 6. Chen X, Liu S, Goraya MU, Maarouf M, Huang S, Chen JL. Host immune response
  290 to Influenza A virus infection. Front Immunol. 2018;9:320. doi:
  291 10.3389/fimmu.2018.00320
- 292 7. Sriwilaijaroen N, Suzuki Y. Molecular basis of the structure and function of H1
  293 hemagglutinin of influenza virus. Proc Jpn Acad Ser B Phys Biol Sci. 2012;88(6):226294 49.
- Altenburg AF, Rimmelzwaan GF, de Vries RD. Virus-specific T cells as correlate of
   (cross-)protective immunity against influenza. Vaccine. 2015;33(4):500-6. doi:
   10.1016/j.vaccine.2014.11.054
- Schrauwen EJ, de Graaf M, Herfst S, Rimmelzwaan GF, Osterhaus AD, Fouchier
   RA. Determinants of virulence of influenza A virus. Eur J Clin Microbiol Infect Dis.
   2014;33(4):479-90. doi: 10.1007/s10096-013-1984-8
- Treanor J. Influenza vaccine--outmaneuvering antigenic shift and drift. N Engl J Med.
  2004;350(3):218-20. doi: 10.1056/NEJMp038238
- 303 11. Gordon A, Reingold A. The burden of influenza: a complex problem. Curr Epidemiol
   304 Rep. 2018;5(1):1-9. doi: 10.1007/s40471-018-0136-1
- Poovorawan Y, Pyungporn S, Prachayangprecha S, Makkoch J. Global alert to avian
  influenza virus infection: from H5N1 to H7N9. Pathog Glob Health. 2013;107(5):217doi: 10.1179/2047773213y.0000000103
- 308 13. Fauci AS. Pandemic influenza threat and preparedness. Emerg Infect Dis.
  309 2006;12(1):73-7. doi: 10.3201/eid1201.050983
- Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and
   ecology of influenza A viruses. Microbiol Rev. 1992;56(1):152-79.
- 312 15. Bouvier NM, Palese P. The biology of influenza viruses. Vaccine. 2008;26 Suppl313 4:D49-53.

- 16. Lloren KKS, Lee T, Kwon JJ, Song MS. Molecular markers for interspecies
  transmission of avian influenza viruses in mammalian hosts. Int J Mol Sci.
  2017;18(12). doi: 10.3390/ijms18122706
- Taubenberger JK, Kash JC. Influenza virus evolution, host adaptation, and pandemic
  formation. Cell Host Microbe. 2010;7(6):440-51. doi: 10.1016/j.chom.2010.05.009
- 18. Fouchier RA, Guan, Y. Ecology and evolution of influenza viruses in wild and
  domestic birds. In: Webster RG, Monto, A.S., Braciale, T.J., Lamb, R.A., editor.
  Textbook of Influenza. London, UK: Wiley; 2013. p. 175–87.
- 19. Peiris JS, de Jong MD, Guan Y. Avian influenza virus (H5N1): a threat to human
  health. Clin Microbiol Rev. 2007;20(2):243-67. doi: 10.1128/cmr.00037-06
- 324 20. Subbarao K, Luke C. H5N1 viruses and vaccines. PLoS Pathog. 2007;3(3):e40. doi:
  325 10.1371/journal.ppat.0030040
- Viboud C, Grais RF, Lafont BA, Miller MA, Simonsen L. Multinational impact of the
  1968 Hong Kong influenza pandemic: evidence for a smoldering pandemic. J Infect
  Dis. 2005;192(2):233-48. doi: 10.1086/431150
- 22. Cox CM, Blanton L, Dhara R, Brammer L, Finelli L. 2009 Pandemic influenza A
  (H1N1) deaths among children--United States, 2009-2010. Clin Infect Dis. 2011;52
  Suppl 1:S69-74. doi: 10.1093/cid/ciq011
- Garcia MN, Philpott DC, Murray KO, Ontiveros A, Revell PA, Chandramohan L, et al.
  Clinical predictors of disease severity during the 2009-2010 A(HIN1) influenza virus
  pandemic in a paediatric population. Epidemiol Infect. 2015;143(14):2939-49. doi:
  10.1017/s0950268815000114
- Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-reactive
  antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med.
  2009;361(20):1945-52. doi: 10.1056/NEJMoa0906453
- 33925.World Health Organization. Report of the WHO Pandemic Influenza A(H1N1)340VaccineDeploymentInitiative
- http://www.who.int/influenza\_vaccines\_plan/resources/h1n1\_deployment\_report.pdf
   [Accessed: 29 March 2018.
- Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng PY, et al. Estimated
  global mortality associated with the first 12 months of 2009 pandemic influenza A
  H1N1 virus circulation: a modelling study. Lancet Infect Dis. 2012;12(9):687-95. doi:
  10.1016/s1473-3099(12)70121-4
- 347 27. Vink C, Rudenko G, Seifert HS. Microbial antigenic variation mediated by
  348 homologous DNA recombination. FEMS Microbiol Rev. 2012;36(5):917-48. doi:
  349 10.1111/j.1574-6976.2011.00321.x

- Haines LR, Hancock RE, Pearson TW. Cationic antimicrobial peptide killing of
  African trypanosomes and Sodalis glossinidius, a bacterial symbiont of the insect
  vector of sleeping sickness. Vector Borne Zoonotic Dis. 2003;3(4):175-86. doi:
  10.1089/153036603322662165
- Kennedy PG. Clinical features, diagnosis, and treatment of human African
  trypanosomiasis (sleeping sickness). Lancet Neurol. 2013;12(2):186-94. doi:
  10.1016/s1474-4422(12)70296-x
- 357 30. Mugnier MR, Stebbins CE, Papavasiliou FN. Masters of disguise: antigenic variation
   and the VSG coat in *Trypanosoma brucei*. PLoS Pathog. 2016;12(9):e1005784. doi:
   10.1371/journal.ppat.1005784
- 360 31. Good MF, Xu H, Wykes M, Engwerda CR. Development and regulation of cell361 mediated immune responses to the blood stages of malaria: implications for vaccine
  362 research. Annu Rev Immunol. 2005;23:69-99. doi:
  363 10.1146/annurev.immunol.23.021704.115638
- 364 32. Wahlgren M, Goel S, Akhouri RR. Variant surface antigens of Plasmodium
  365 falciparum and their roles in severe malaria. Nat Rev Microbiol. 2017;15(8):479-91.
  366 doi: 10.1038/nrmicro.2017.47
- 367 33. Stone WJR, Campo JJ, Ouedraogo AL, Meerstein-Kessel L, Morlais I, Da D, et al.
  368 Unravelling the immune signature of *Plasmodium falciparum* transmission-reducing
  369 immunity. Nat Commun. 2018;9(1):558. doi: 10.1038/s41467-017-02646-2
- 370 34. D'Ombrain MC, Voss TS, Maier AG, Pearce JA, Hansen DS, Cowman AF, et al.
  371 Plasmodium falciparum erythrocyte membrane protein-1 specifically suppresses
  372 early production of host interferon-gamma. Cell Host Microbe. 2007;2(2):130-8. doi:
  373 10.1016/j.chom.2007.06.012
- 374 35. Kim K. Malaria var gene expression: keeping up with the neighbors. Cell Host
  375 Microbe. 2012;11(1):1-2. doi: 10.1016/j.chom.2012.01.002
- 376 36. Chintalacharuvu KR, Chuang PD, Dragoman A, Fernandez CZ, Qiu J, Plaut AG, et
  377 al. Cleavage of the human immunoglobulin A1 (IgA1) hinge region by IgA1 proteases
  378 requires structures in the Fc region of IgA. Infect Immun. 2003;71(5):2563-70.
- 379 37. Chi YC, Rahkola JT, Kendrick AA, Holliday MJ, Paukovich N, Roberts TS, et al.
  380 Streptococcus pneumoniae IgA1 protease: A metalloprotease that can catalyze in a
  381 split manner in vitro. Prot Sci. 2017;26(3):600-10. doi: 10.1002/pro.3110 [doi]
- 382 38. Kilian M, Reinholdt J, Lomholt H, Poulsen K, Frandsen EV. Biological significance of
  383 IgA1 proteases in bacterial colonization and pathogenesis: critical evaluation of
  384 experimental evidence. APMIS. 1996;104(5):321-38.
- 385 39. Woof JM, Kerr MA. The function of immunoglobulin A in immunity. J Pathol.
  386 2006;208(2):270-82. doi: 10.1002/path.1877 [doi]

- 40. Hedges SR, Mayo MS, Kallman L, Mestecky J, Hook EW, 3rd, Russell MW.
  Evaluation of immunoglobulin A1 (IgA1) protease and IgA1 protease-inhibitory
  activity in human female genital infection with *Neisseria gonorrhoeae*. Infect Immun.
  1998;66(12):5826-32.
- 41. Ahl T, Reinholdt J. Detection of immunoglobulin A1 protease-induced Fab alpha
  fragments on dental plaque bacteria. Infect Immun. 1991;59(2):563-9.
- Fick RB, Jr., Baltimore RS, Squier SU, Reynolds HY. IgG proteolytic activity of
   *Pseudomonas aeruginosa* in cystic fibrosis. J Infect Dis. 1985;151(4):589-98.
- Brezski RJ, Luongo JL, Petrone D, Ryan MH, Zhong D, Tam SH, et al. Human antiIgG1 hinge autoantibodies reconstitute the effector functions of proteolytically
  inactivated IgGs. J Immunol. 2008;181(5):3183-92. doi: 181/5/3183 [pii]
- 398 44. Brezski RJ, Jordan RE. Cleavage of IgGs by proteases associated with invasive
  399 diseases: an evasion tactic against host immunity? mAbs. 2010;2(3):212-20. doi:
  400 11780 [pii]
- 401 45. Sulica A, Medesan C, Laky M, Onica D, Sjoquist J, Ghetie V. Effect of protein A of
  402 *Staphylococcus aureus* on the binding of monomeric and polymeric IgG to Fc
  403 receptor-bearing cells. Immunology. 1979;38(1):173-9.
- 404
  46. lijima M, Kadoya H, Hatahira S, Hiramatsu S, Jung G, Martin A, et al. Nanocapsules
  incorporating IgG Fc-binding domain derived from *Staphylococcus aureus* protein A
  for displaying IgGs on immunosensor chips. Biomaterials. 2011;32(6):1455-64. doi:
  10.1016/j.biomaterials.2010.10.057 [doi]
- 408 47. Foster TJ, Geoghegan JA, Ganesh VK, Hook M. Adhesion, invasion and evasion: the
  409 many functions of the surface proteins of *Staphylococcus aureus*. Nature Rev
  410 Microbiol. 2014;12(1):49-62. doi: 10.1038/nrmicro3161 [doi]
- 411 48. Wikstrom M, Drakenberg T, Forsen S, Sjobring U, Bjorck L. Three-dimensional
  412 solution structure of an immunoglobulin light chain-binding domain of protein L.
  413 Comparison with the IgG-binding domains of protein G. Biochemistry.
  414 1994;33(47):14011-7.
- 415 49. Kihlberg BM, Sjoholm AG, Bjorck L, Sjobring U. Characterization of the binding
  416 properties of protein LG, an immunoglobulin-binding hybrid protein. Eur J Biochem.
  417 1996;240(3):556-63.
- 418 50. Ricci S, Medaglini D, Marcotte H, Olsen A, Pozzi G, Bjorck L. Immunoglobulin419 binding domains of Peptostreptococcal protein L enhance vaginal colonization of
  420 mice by Streptococcus gordonii. Microb Pathogen. 2001;30(4):229-35. doi:
  421 10.1006/mpat.2000.0427 [doi]

- Elbim C, Bailly S, Chollet-Martin S, Hakim J, Gougerot-Pocidalo MA. Differential
  priming effects of proinflammatory cytokines on human neutrophil oxidative burst in
  response to bacterial N-formyl peptides. Infect Immun. 1994;62(6):2195-201.
- 425 52. Videm V, Strand E. Changes in neutrophil surface-receptor expression after
  426 stimulation with FMLP, endotoxin, interleukin-8 and activated complement compared
  427 to degranulation. Scand J Immunol. 2004;59(1):25-33. doi: 1351 [pii]
- Murphy PM, Ozcelik T, Kenney RT, Tiffany HL, McDermott D, Francke U. A structural
  homologue of the N-formyl peptide receptor. Characterization and chromosome
  mapping of a peptide chemoattractant receptor family. J Biol Chem.
  1992;267(11):7637-43.
- 432 54. Prossnitz ER, Ye RD. The N-formyl peptide receptor: a model for the study of
  433 chemoattractant receptor structure and function. Pharmacol Ther. 1997;74(1):73-102.
  434 doi: S0163725896002033 [pii]
- 435 55. Le Y, Murphy PM, Wang JM. Formyl-peptide receptors revisited. Trends Immunol.
  436 2002;23(11):541-8. doi: S1471490602023165 [pii]
- 437 56. Veldkamp KE, Heezius HC, Verhoef J, van Strijp JA, van Kessel KP. Modulation of
  438 neutrophil chemokine receptors by *Staphylococcus aureus* supernate. Infect Immun.
  439 2000;68(10):5908-13.
- 440 57. Prat C, Haas PJ, Bestebroer J, de Haas CJ, van Strijp JA, van Kessel KP. A homolog
  441 of formyl peptide receptor-like 1 (FPRL1) inhibitor from *Staphylococcus aureus*442 (FPRL1 inhibitory protein) that inhibits FPRL1 and FPR. J Immunol.
  443 2009;183(10):6569-78. doi: 10.4049/jimmunol.0801523 [doi]
- 444 58. Postma B, Poppelier MJ, van Galen JC, Prossnitz ER, van Strijp JA, de Haas CJ, et
  445 al. Chemotaxis inhibitory protein of *Staphylococcus aureus* binds specifically to the
  446 C5a and formylated peptide receptor. J Immunol. 2004;172(11):6994-7001.
- 447 59. de Jong NWM, Vrieling M, Garcia BL, Koop G, Brettmann M, Aerts PC, et al.
  448 Identification of a Staphylococcal Complement Inhibitor with broad host specificity in
  449 equid S. aureus strains. J Biol Chem. 2018. doi: 10.1074/jbc.RA117.000599
- 60. Rooijakkers SH, Wu J, Ruyken M, van Domselaar R, Planken KL, Tzekou A, et al.
  Structural and functional implications of the alternative complement pathway C3
  convertase stabilized by a staphylococcal inhibitor. Nat Immunol. 2009;10(7):721-7.
  doi: 10.1038/ni.1756 [doi]
- Garcia BL, Summers BJ, Lin Z, Ramyar KX, Ricklin D, Kamath DV, et al. Diversity in
  the C3b [corrected] contact residues and tertiary structures of the staphylococcal
  complement inhibitor (SCIN) protein family. J Biol Chem. 2012;287(1):628-40. doi:
  10.1074/jbc.M111.298984 [doi]

- 458 62. Ricklin D, Tzekou A, Garcia BL, Hammel M, McWhorter WJ, Sfyroera G, et al. A
  459 molecular insight into complement evasion by the staphylococcal complement
  460 inhibitor protein family. J Immunol. 2009;183(4):2565-74. doi:
  461 10.4049/jimmunol.0901443 [doi]
- 462 63. Lee LY, Hook M, Haviland D, Wetsel RA, Yonter EO, Syribeys P, et al. Inhibition of
  463 complement activation by a secreted *Staphylococcus aureus* protein. J Infect Dis.
  464 2004;190(3):571-9. doi: 10.1086/422259 [doi]
- 465 64. Rooijakkers SH, Ruyken M, Roos A, Daha MR, Presanis JS, Sim RB, et al. Immune
  466 evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat
  467 Immunol. 2005;6(9):920-7. doi: ni1235 [pii]
- 468 65. Verkaik NJ, Benard M, Boelens HA, de Vogel CP, Nouwen JL, Verbrugh HA, et al.
  469 Immune evasion cluster-positive bacteriophages are highly prevalent among human
  470 *Staphylococcus aureus* strains, but they are not essential in the first stages of nasal
  471 colonization. Clin Microbiol Infect. 2011;17(3):343-8. doi: 10.1111/j.1469472 0691.2010.03227.x [doi]
- 473 66. van Wamel WJ, Rooijakkers SH, Ruyken M, van Kessel KP, van Strijp JA. The innate
  474 immune modulators staphylococcal complement inhibitor and chemotaxis inhibitory
  475 protein of *Staphylococcus aureus* are located on beta-hemolysin-converting
  476 bacteriophages. J Bacteriol. 2006;188(4):1310-5. doi: 188/4/1310 [pii]
- 477 67. Kotwal GJ, Isaacs SN, McKenzie R, Frank MM, Moss B. Inhibition of the complement
  478 cascade by the major secretory protein of vaccinia virus. Science.
  479 1990;250(4982):827-30.
- 480 68. Meseda CA, Kuhn J, Atukorale V, Campbell J, Weir JP. Glycosylated and
  481 nonglycosylated complement control protein of the lister strain of vaccinia virus. Clin
  482 Vaccine Immunol. 2014;21(9):1330-8. doi: 10.1128/cvi.00347-14
- 483 69. McKenzie R, Kotwal GJ, Moss B, Hammer CH, Frank MM. Regulation of complement
  484 activity by vaccinia virus complement-control protein. J Infect Dis. 1992;166(6):1245485 50.
- 486 70. Sahu A, Isaacs SN, Soulika AM, Lambris JD. Interaction of vaccinia virus
  487 complement control protein with human complement proteins: factor I-mediated
  488 degradation of C3b to iC3b1 inactivates the alternative complement pathway. J
  489 Immunol. 1998;160(11):5596-604.
- 490 71. Spear PG. Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol.
  491 2004;6(5):401-10. doi: 10.1111/j.1462-5822.2004.00389.x [doi]
- 492 72. Miranda-Saksena M, Denes CE, Diefenbach RJ, Cunningham AL. Infection and
  493 transport of Herpes Simplex virus Type 1 in neurons: role of the cytoskeleton.
  494 Viruses. 2018;10(2):10.3390/v10020092. doi: E92 [pii]

- 495 73. Cunningham AL, Diefenbach RJ, Miranda-Saksena M, Bosnjak L, Kim M, Jones C, et
  496 al. The cycle of human herpes simplex virus infection: virus transport and immune
  497 control. J Infect Dis. 2006;194 Suppl 1:11. doi: JID35844 [pii]
- 498 74. Izumi KM, Cahir McFarland ED, Riley EA, Rizzo D, Chen Y, Kieff E. The residues
  499 between the two transformation effector sites of Epstein-Barr virus latent membrane
  500 protein 1 are not critical for B-lymphocyte growth transformation. J Virol.
  501 1999;73(12):9908-16.
- 502 75. Levitskaya J, Sharipo A, Leonchiks A, Ciechanover A, Masucci MG. Inhibition of
  503 ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of
  504 the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci USA.
  505 1997;94(23):12616-21.
- 506 76. Daskalogianni C, Pyndiah S, Apcher S, Mazars A, Manoury B, Ammari N, et al.
  507 Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies
  508 against EBV-carrying cancers. J Pathol. 2015;235(2):334-41. doi: 10.1002/path.4431
  509 [doi]
- Apcher S, Daskalogianni C, Manoury B, Fahraeus R. Epstein Barr virus-encoded
  EBNA1 interference with MHC class I antigen presentation reveals a close
  correlation between mRNA translation initiation and antigen presentation. PLoS
  Pathog. 2010;6(10):e1001151. doi: 10.1371/journal.ppat.1001151 [doi]
- 514 78. Ploegh HL. Viral strategies of immune evasion. Science. 1998;280(5361):248-53.
- 515 79. Hengel H, Brune W, Koszinowski UH. Immune evasion by cytomegalovirus--survival
  516 strategies of a highly adapted opportunist. Trends Microbiol. 1998;6(5):190-7. doi:
  517 S0966-842X(98)01255-4 [pii]
- 518 80. Furman MH, Dey N, Tortorella D, Ploegh HL. The human cytomegalovirus US10
  519 gene product delays trafficking of major histocompatibility complex class I molecules.
  520 J Virol. 2002;76(22):11753-6.
- 521 81. Jones TR, Wiertz EJ, Sun L, Fish KN, Nelson JA, Ploegh HL. Human 522 cytomegalovirus US3 impairs transport and maturation of major histocompatibility 523 complex class I heavy chains. Proc Natl Acad Sci USA. 1996;93(21):11327-33.
- 82. Wiertz EJ, Jones TR, Sun L, Bogyo M, Geuze HJ, Ploegh HL. The human
  cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the
  endoplasmic reticulum to the cytosol. Cell. 1996;84(5):769-79. doi: S00928674(00)81054-5 [pii]
- 83. Wiertz EJ, Tortorella D, Bogyo M, Yu J, Mothes W, Jones TR, et al. Sec61-mediated
  transfer of a membrane protein from the endoplasmic reticulum to the proteasome for
  destruction. Nature. 1996;384(6608):432-8. doi: 10.1038/384432a0 [doi]

- 531 84. Halenius A, Gerke C, Hengel H. Classical and non-classical MHC I molecule 532 manipulation by human cytomegalovirus: so many targets-but how many arrows in 533 the guiver? Cell Mol Immunol. 2015;12(2):139-53. doi: 10.1038/cmi.2014.105 [doi]
- 534 85. Lin A, Xu H, Yan W. Modulation of HLA expression in human cytomegalovirus 535 immune evasion. Cell Mol Immunol. 2007;4(2):91-8.
- 536 86. Yang Z, Bjorkman PJ. Structure of UL18, a peptide-binding viral MHC mimic, bound
  537 to a host inhibitory receptor. Proc Natl Acad Sci USA. 2008;105(29):10095-100. doi:
  538 10.1073/pnas.0804551105 [doi]
- Schonrich G, Abdelaziz MO, Raftery MJ. Herpesviral capture of immunomodulatory
  host genes. Virus Genes. 2017;53(6):762-73. doi: 10.1007/s11262-017-1460-0
- 541 88. Scarborough JA, Paul JR, Spencer JV. Evolution of the ability to modulate host
  542 chemokine networks via gene duplication in human cytomegalovirus (HCMV). Infect
  543 Genet Evol. 2017;51:46-53. doi: 10.1016/j.meegid.2017.03.013
- Kuo NW, Gao YG, Schill MS, Isern N, Dupureur CM, Liwang PJ. Structural insights
  into the interaction between a potent anti-inflammatory protein, viral CC chemokine
  inhibitor (vCCI), and the human CC chemokine, Eotaxin-1. J Biol Chem.
  2014;289(10):6592-603. doi: 10.1074/jbc.M113.538991
- McSharry BP, Avdic S, Slobedman B. Human cytomegalovirus encoded homologs of
  cytokines, chemokines and their receptors: roles in immunomodulation. Viruses.
  2012;4(11):2448-70. doi: 10.3390/v4112448
- Jochum S, Moosmann A, Lang S, Hammerschmidt W, Zeidler R. The EBV
  immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune
  recognition and elimination. PLoS Pathog. 2012;8(5):e1002704. doi:
  10.1371/journal.ppat.1002704
- 555 92. Sin SH, Dittmer, D.P. Cytokine homologs of human gammaherpesviruses. J 556 Interferon Cytokine Res. 2012;32(2):53-9.
- 93. Pflanz S, Timans, J.C., Cheung, J., Rosales, R., Kanzler, H., Gilbert, J., Hibbert, L.,
  Churakova, T., Travis, M., Vaisberg, E., Blumenschein, W.M., Mattson, J.D., Wagner,
  J.L., To, W., Zurawski, S., McClanahan, T.K., Gorman, D.M., Bazan, J.F., de Waal
  Malefyt, R., Rennick, D., Kastelein, R.A. . IL-27, a heterodimeric cytokine composed
  of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity.
  2002;16(6):779-90.
- 563 94. Haig DM. Poxvirus interference with the host cytokine response. Vet Immunol 564 Immunopathol. 1998;63(1-2):149-56.
- 565 95. Vecchiarelli A, Retini C, Pietrella D, Monari C, Tascini C, Beccari T, et al. 566 Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and

- interleukin-1 beta secretion from human monocytes. Infect Immun. 1995;63(8):2919-23.
- 569 96. Sprague ER, Reinhard H, Cheung EJ, Farley AH, Trujillo RD, Hengel H, et al. The 570 human cytomegalovirus Fc receptor gp68 binds the Fc CH2-CH3 interface of 571 immunoglobulin G. J Virol. 2008;82(7):3490-9. doi: 10.1128/jvi.01476-07
- 572 97. Lubinski JM, Jiang M, Hook L, Chang Y, Sarver C, Mastellos D, et al. Herpes simplex
  573 virus type 1 evades the effects of antibody and complement in vivo. J Virol.
  574 2002;76(18):9232-41.
- 575 98. Kvansakul M, Caria S, Hinds MG. The Bcl-2 family in host-virus interactions. Viruses.
  576 2017;9(10). doi: 10.3390/v9100290
- 577 99. Lotzerich M, Roulin PS, Boucke K, Witte R, Georgiev O, Greber UF. Rhinovirus 3C
  578 protease suppresses apoptosis and triggers caspase-independent cell death. Cell
  579 Death Dis. 2018;9(3):272. doi: 10.1038/s41419-018-0306-6
- Tabtieng T, Degterev A, Gaglia MM. Caspase-dependent suppression of type I
  interferon signaling promotes KSHV lytic replication. J Virol. 2018. doi:
  10.1128/jvi.00078-18
- 583 101. Yu E, Zhai D, Jin C, Gerlic M, Reed JC, Liddington R. Structural determinants of
  584 caspase-9 inhibition by the vaccinia virus protein, F1L. J Biol Chem.
  585 2011;286(35):30748-58. doi: 10.1074/jbc.M111.280149
- 586

587 REVIEWER: DR FESTUS D. OTAJEVWO

- 588 MEDICAL MICROBIOLOGIST/MEDICAL LABORATORY SCIENTIST
- 589 WESTERN DELTA UNIVERSITY, OGHARA, NIGERIA.